| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New York Medical College, Department of Pharmacology and Medicine, Valhalla, New York (N.G.A.); and Rockefeller University Hospital, New York, New York (N.G.A., A.K.)
This review is intended to stimulate interest in the effect of increased expression of heme oxygenase-1 (HO-1) protein and increased levels of HO activity on normal and pathological states. The HO system includes the heme catabolic pathway, comprising HO and biliverdin reductase, and the products of heme degradation, carbon monoxide (CO), iron, and biliverdin/bilirubin. The role of the HO system in diabetes, inflammation, heart disease, hypertension, neurological disorders, transplantation, endotoxemia and other pathologies is a burgeoning area of research. This review focuses on the clinical potential of increased levels of HO-1 protein and HO activity to ameliorate tissue injury. The use of pharmacological and genetic probes to manipulate HO, leading to new insights into the complex relationship of the HO system with biological and pathological phenomena under investigation, is reviewed. This information is critical in both drug development and the implementation of clinical approaches to moderate and to alleviate the numerous chronic disorders in humans affected by perturbations in the HO system.
Abstract I. Introduction II. Heme Degradative Pathway A. Characterization of Heme Oxygenase B. Heme Oxygenase Isozymes C. Heme Oxygenase and the Heme Pool D. Heme Oxygenase-NADPH Biliverdin Reductase III. Pathophysiology of and Clinical Role of Heme Oxygenase-1/Heme Oxygenase-2: Reaction Products A. Increased Levels of Heme Oxygenase-1 and Heme Oxygenase Activity 1. Acute Effects. 2. Chronic Effects. B. Role of Carbon Monoxide C. Role of Bilirubin/Biliverdin D. Role of Iron and Ferritin IV. Heme Oxygenase in Disease A. Hypoxia and Ischemia B. Corneal Inflammation C. Hyperbilirubinemia 1. Neonatal Jaundice. 2. Clinical Use of Heme Oxygenase Inhibitors. D. Heme Oxygenase-1 in Diabetes and Obesity E. Heme Oxygenase-1 in Atherosclerosis 1. Endothelial Dysfunction and Vascular Injury. 2. Inflammation and Vascular Injury. 3. Smooth Muscle Cell Proliferation and Vascular Injury. 4. Vasodilatation and Vascular Function. F. Heme Oxygenase-1 in Myocardial Ischemia-Reperfusion Injury G. Cardiovascular Drugs and Drug Developments Targeting Heme Oxygenase-1 Gene Expression 1. Aspirin. 2. Statins. 3. Amino Acid Apolipoprotein A-I L-4F and D-4F Mimetic Peptides. 4. Probucol. 5. Losartan. 6. Paclitaxel. 7. Rapamycin. 8. Immunosuppressive Drugs. 9. Curcumin. 10. Resveratrol. H. Heme Oxygenase-1 and Cardiovascular Disease: Therapeutic Rationale I. Acute Kidney Injury and Heme Oxygenase-1/Heme Oxygenase-2 J. Heme Oxygenase-1 and Hypertension 1. Blood Pressure Regulation. 2. Renovascular Hypertension. 3. Pulmonary Hypertension. 4. Portal Hypertension. K. Hepatic Injury L. Hormonal Regulation M. Stromal/Mesenchymal Stem Cells and Hematopoiesis N. Infectious Disease and Heme Oxygenase-1 O. Cancer and Heme Oxygenase-1 P. Aging, Parkinson's Disease, and Alzheimer's Disease 1. Alzheimer's Disease. 2. Parkinson's Disease. Q. Brain Hemorrhage and Heme Oxygenase System 1. Subarachnoid Hemorrhage. 2. Intracerebral Hemorrhage. 3. Stroke. V. Summary
This article has been cited by other articles:
|
|
 |
|
  S. J. Peterson, D. H. Kim, M. Li, V. Positano, L. Vanella, L. F. Rodella, F. Piccolomini, N. Puri, A. Gastaldelli, C. Kusmic, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice J. Lipid Res., July 1, 2009; 50(7): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jadhav and J. F. Ndisang Heme Arginate Suppresses Cardiac Lesions and Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertension Experimental Biology and Medicine, July 1, 2009; 234(7): 764 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassalli, M.-E. Roehrich, P. Vogt, G. B. Pedrazzini, F. Siclari, T. Moccetti, and L. K. von Segesser Modalities and future prospects of gene therapy in heart transplantation Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1036 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shu, A. Royant, M. Z. Lin, T. A. Aguilera, V. Lev-Ram, P. A. Steinbach, and R. Y. Tsien Mammalian Expression of Infrared Fluorescent Proteins Engineered from a Bacterial Phytochrome Science, May 8, 2009; 324(5928): 804 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Ndisang, N. Lane, and A. Jadhav Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1029 - E1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-M. Sue, C.-F. Cheng, C.-C. Chang, Y. Chou, C.-H. Chen, and S.-H. Juan Antioxidation and anti-inflammation by haem oxygenase-1 contribute to protection by tetramethylpyrazine against gentamicin-induced apoptosis in murine renal tubular cells Nephrol. Dial. Transplant., March 1, 2009; 24(3): 769 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O De Backer, E Elinck, B Blanckaert, L Leybaert, R Motterlini, and R A Lefebvre Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress Gut, March 1, 2009; 58(3): 347 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Hassan and K. Gronert Acute Changes in Dietary {omega}-3 and {omega}-6 Polyunsaturated Fatty Acids Have a Pronounced Impact on Survival following Ischemic Renal Injury and Formation of Renoprotective Docosahexaenoic Acid-Derived Protectin D1 J. Immunol., March 1, 2009; 182(5): 3223 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Basuroy, S. Bhattacharya, C. W. Leffler, and H. Parfenova Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-{alpha} in cerebral vascular endothelial cells Am J Physiol Cell Physiol, March 1, 2009; 296(3): C422 - C432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nicolai, M. Li, D. H. Kim, S. J. Peterson, L. Vanella, V. Positano, A. Gastaldelli, R. Rezzani, L. F. Rodella, G. Drummond, et al. Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats Hypertension, March 1, 2009; 53(3): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Di Francesco, L. Totani, M. Dovizio, A. Piccoli, A. Di Francesco, T. Salvatore, A. Pandolfi, V. Evangelista, R. A. Dercho, F. Seta, et al. Induction of Prostacyclin by Steady Laminar Shear Stress Suppresses Tumor Necrosis Factor-{alpha} Biosynthesis via Heme Oxygenase-1 in Human Endothelial Cells Circ. Res., February 27, 2009; 104(4): 506 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sambuceti, S. Morbelli, L. Vanella, C. Kusmic, C. Marini, M. Massollo, C. Augeri, M. Corselli, C. Ghersi, B. Chiavarina, et al. Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage, Reversed by Increases in pAMPK, Heme Oxygenase-1, and Adiponectin Stem Cells, February 1, 2009; 27(2): 399 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Tracz, J. P. Juncos, J. P. Grande, A. J. Croatt, A. W. Ackerman, Z. S. Katusic, and K. A. Nath Induction of Heme Oxygenase-1 is a Beneficial Response in a Murine Model of Venous Thrombosis Am. J. Pathol., December 1, 2008; 173(6): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jadhav, E. Torlakovic, and J. F. Ndisang Interaction Among Heme Oxygenase, Nuclear Factor-{kappa}B, and Transcription Activating Factors in Cardiac Hypertrophy in Hypertension Hypertension, November 1, 2008; 52(5): 910 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ren, M. A. D'Ambrosio, H. Wang, R. Liu, J. L. Garvin, and O. A. Carretero Heme oxygenase metabolites inhibit tubuloglomerular feedback (TGF) Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1207 - F1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Abraham Gene Targeting and Heme Oxygenase-1 Expression in Prevention of Hypertension Induced by Angiotensin II Hypertension, October 1, 2008; 52(4): 618 - 620. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li Calzi, D. L. Purich, K. H. Chang, A. Afzal, T. Nakagawa, J. V. Busik, A. Agarwal, M. S. Segal, and M. B. Grant Carbon Monoxide and Nitric Oxide Mediate Cytoskeletal Reorganization in Microvascular Cells via Vasodilator-Stimulated Phosphoprotein Phosphorylation: Evidence for Blunted Responsiveness in Diabetes Diabetes, September 1, 2008; 57(9): 2488 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Peterson, G. Drummond, D. H. Kim, M. Li, A. L. Kruger, S. Ikehara, and N. G. Abraham L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice J. Lipid Res., August 1, 2008; 49(8): 1658 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kim, A. P. Burgess, M. Li, P. L. Tsenovoy, F. Addabbo, J. A. McClung, N. Puri, and N. G. Abraham Heme Oxygenase-Mediated Increases in Adiponectin Decrease Fat Content and Inflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-6 in Zucker Rats and Reduce Adipogenesis in Human Mesenchymal Stem Cells J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, D. H. Kim, P. L. Tsenovoy, S. J. Peterson, R. Rezzani, L. F. Rodella, W. S. Aronow, S. Ikehara, and N. G. Abraham Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance Diabetes, June 1, 2008; 57(6): 1526 - 1535. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
